Captis reveal™, a data sharing resource developed with Captis partner aptitude LLC, allows members and suppliers to access powerful insights that help maximize compliance and understand overall performance. Captis-contracted suppliers use the account management tools specifically related to purchase intelligence to not only review market share, but understand what is influencing purchasing patterns within the membership.
Members utilize the same information to identify opportunities for additional savings through contract optimization. This transparency opens the door to more informed member-supplier partnerships and evolves their discussion beyond price.
Julie Trebus, system director of strategic sourcing, procurement and value analysis at Aspirus, has experienced the benefits of Reveal first hand. "We performed a business review and discussed the results from the Reveal tool with one of our suppliers," Julie said. "Aspirus was underutilizing the products available to us and without this conversation; we would have continued to miss out on savings."
The information available to suppliers supports Captis members in their conversion and contract performance efforts, and in preparing trial product packages in anticipation of contract launches.
"This was an opportunity for them to assist us in achieving greater contract savings and rebates, while ensuring compliance with the contract," Julie said. "The way that they used this tool makes us want to use it even more because it finds potential cost savings and outlines opportunities where we can improve. This transparent conversation around contract compliance has strengthened our relationship."
The way that they used this tool makes us want to use it even more because it finds potential cost savings and outlines opportunities where we can improve. This transparent conversation around contract compliance has strengthened our relationship.Julie TrebusSystem Director of Strategic Sourcing
Procurement and Value Analysis,
Blood transfusion is acknowledged as a needed therapy, but it comes with patient safety risks and added costs. It is important to optimize red blood cell (RBC) transfusion practice. Each organization’s quality program must address the use of blood and blood components, requiring the development of a cross-functional group of medical and support staff charged with the responsibility of blood usage oversight. Improved blood management can reduce usage and complication rates by 30 to 50 percent. The Blood Management program aligns Captis members’ clinical behavior with protocols supported by evidence-based national blood standards. Captis members have not only benefitted by the millions from their conservation and administration protocol efforts, they are benefitting from a collaborative learning and data gathering environment that helps keep their patients safe.
“This program has brought many different silos together; there is a combination of different resources to learn from during the presentations; industry experts and member hospitals. The training and education provides best practices you can infuse into your own program. We realized we are part of a program with recognized professionals and hospitals focused on this sole topic. The multi-pronged approach merges our experience from the field and scientifically based information.
We have a young free standing Emergency Department and we knew our blood usage had been minimal but we hadn’t performed a full audit on the number of products transfused, the number of patients who received those products and the outcome for those patients. Our review consistently indicated there was an emergent need, the right product was administered at the right time, in the right place and with the right follow up. This is a reoccurring practice now and we know we are doing it right. This is exactly what the program was designed to do. This was a new audit recommended by another member during one of our calls and it showed very positive results.”
Sheila Phillips, MHS, MT (ASCP)Administrative director
NCH Healthcare Systems – Community Blood Center
“It’s turned into a very valuable and useful endeavor due to the collaborative nature and having others with whom you can share ideas. With the physicians on the line we can ask questions and benefit from having a readily available resource to ask how to explore outliers. It has been impactful to see our steadily decreasing blood use.
Having standardized data allows us to benchmark ourselves to other organizations and know that we are comparing on a level playing field.
There is significant savings but the real benefit is the safety for our patients. If we don’t have to give a transfusion we are providing the best care and the safest approach.”
Dean Porter, MLS (ASCP)Laboratory administrative director
Ridgeview Medical Center and Clinics
The Custom Procedure Tray (CPT) partnership between Captis and Medline Industries, Inc., provides efficiencies for both members and suppliers, and improves patient care, by identifying cost drivers and by standardizing preferred componentry and product formulary across the Captis membership.
In 2017, the Captis CPT program embarked on a mission to reduce the number of components used, and to increase consistency across the Captis membership. With the support of the Mayo Clinic Quality Value Analysis (CQVA) Team, 281 components were reviewed on behalf of the membership and formulary products identified. Members are given a specified timeframe to review the formulary products and request samples. Pack changes go into effect on the same day for the entire membership.
"Formulary analysis identifies high quality products, savings and supply chain efficiencies" said Troy Bolton, director of marketing for Medline’s Sterile Procedure Division. Over the course of the year, Captis, its members and Medline were able to reduce the number of unique components used by 34% and garner an associated $500,000 in member savings. "This highlights the success of what a collaboration like Captis can do," said Troy.
Terri Nelson, RN MA, director of supply chain operations, CQVA at Mayo Clinic led the clinical review of proposed components. "We are consistent in following a standardized value analysis process and documenting what is found within it," said Terri. "We are aligning clinically by gathering input from clinical users, the FDA and suppliers." The team maintains a critical eye in evaluating what components will bring the best value, the best patient outcomes and clinical experiences. "If there isn’t a compelling clinical reason why our members are using a product, and there is value to be attained, conversion activity is recommended," said Terri.
Even the smallest of changes can have a big impact on an organization; collaboration and communication builds awareness and positions the project for success. "We requested sample products for our O.R. staff and took the anxiety of a product change out," shared Dave Weigel, director of supply chain for Prairie Lakes Healthcare System. "If they get their hands on it in advance, it reduces anxiety, frustration and not knowing if you are going to have what you need for surgery. We don’t want them to be surprised."
During their very first round of conversion to the formulary products, Prairie Lakes received samples and convened its stakeholders. "After reviewing the third or fourth item," Dave shared, "they expressed a high comfort level and confirmed that they couldn’t tell a difference between items. Now, in most cases they are fine with just reviewing a list of products slated for conversion; that wouldn’t have worked the same if I would have just told them to ‘trust me’ at the beginning of this process."
With new drugs entering the market, drug prices on the rise and new regulations around every corner, Captis members are working together to collectively address safety, quality and cost reduction.
The Captis Pharmacy Program includes:
The Pharmacy Council and Finance Committee revised the billing methodology which reduced pharmacy program fees for 88% of Captis members.
Two cost avoidance initiatives were identified, formulary products were instituted and utilization was managed to achieve best in class pricing. With this effort, Captis members avoided over $10 million in drug costs.
20 drug contracts are now in place, $15.7 million in savings was achieved and additional collaborative programs such as compounding, Drug Supply Chain Securities Act (DSCSA) and specialty pharmacy were advanced.
Contracts in the portfolio
Savings (including utilization)